Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

High resolution crystal structure of a human tumor necrosis factor-alpha mutant with low systemic toxicity.

Cha SS, Kim JS, Cho HS, Shin NK, Jeong W, Shin HC, Kim YJ, Hahn JH, Oh BH.

J Biol Chem. 1998 Jan 23;273(4):2153-60.

2.

Human tumor necrosis factor mutants with preferential binding to and activity on either the R55 or R75 receptor.

Van Ostade X, Vandenabeele P, Tavernier J, Fiers W.

Eur J Biochem. 1994 Mar 15;220(3):771-9.

4.

Crystal structure of TNF-alpha mutant R31D with greater affinity for receptor R1 compared with R2.

Reed C, Fu ZQ, Wu J, Xue YN, Harrison RW, Chen MJ, Weber IT.

Protein Eng. 1997 Oct;10(10):1101-7.

PMID:
9488135
5.

Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.

Mukai Y, Shibata H, Nakamura T, Yoshioka Y, Abe Y, Nomura T, Taniai M, Ohta T, Ikemizu S, Nakagawa S, Tsunoda S, Kamada H, Yamagata Y, Tsutsumi Y.

J Mol Biol. 2009 Jan 30;385(4):1221-9. doi: 10.1016/j.jmb.2008.11.053. Epub 2008 Dec 6.

PMID:
19084540
6.

A novel recombinant tumor necrosis factor-alpha mutant with increased anti-tumor activity and lower toxicity.

Nakamura S, Kato A, Masegi T, Fukuoka M, Kitai K, Ogawa H, Ichikawa Y, Maeda M, Watanabe N, Kohgo Y, et al.

Int J Cancer. 1991 Jul 9;48(5):744-8.

PMID:
1649139
7.

Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist.

Shibata H, Yoshioka Y, Ohkawa A, Minowa K, Mukai Y, Abe Y, Taniai M, Nomura T, Kayamuro H, Nabeshi H, Sugita T, Imai S, Nagano K, Yoshikawa T, Fujita T, Nakagawa S, Yamamoto A, Ohta T, Hayakawa T, Mayumi T, Vandenabeele P, Aggarwal BB, Nakamura T, Yamagata Y, Tsunoda S, Kamada H, Tsutsumi Y.

J Biol Chem. 2008 Jan 11;283(2):998-1007. Epub 2007 Nov 14.

8.

A novel tumor necrosis factor-alpha mutant with significantly enhanced cytotoxicity and receptor binding affinity.

Shin NK, Lee I, Chang SG, Shin HC.

Biochem Mol Biol Int. 1998 May;44(6):1075-82.

PMID:
9623760
9.

Human TNF mutants with selective activity on the p55 receptor.

Van Ostade X, Vandenabeele P, Everaerdt B, Loetscher H, Gentz R, Brockhaus M, Lesslauer W, Tavernier J, Brouckaert P, Fiers W.

Nature. 1993 Jan 21;361(6409):266-9.

PMID:
8380906
10.

Determination of the limited trypsinolysis pathways of tumor necrosis factor-alpha and its mutant by electrospray ionization mass spectrometry.

Kim YJ, Cha SS, Kim JS, Shin NK, Jeong W, Shin HC, Oh BH, Hahn JH.

Anal Biochem. 1999 Feb 15;267(2):279-86.

PMID:
10036131
11.

Tumor necrosis factor mutants with selective cytotoxic activity.

Berkova N, Lemay A, Korobko V, Shingarova L, Sagaidak L, Goupil S.

Cancer Detect Prev. 1999;23(1):1-7.

PMID:
9892984
12.

Effect of gene transfer of tumor necrosis factor receptors into human lung carcinoma cell line.

Ohara H, Hasegawa Y, Kawabe T, Ichiyama S, Hara T, Shimono Y, Saito H, Shimokata K.

Jpn J Cancer Res. 1998 May;89(5):589-95.

13.

Interactions between novel tumor necrosis factor-alpha mutants and receptors on tumor and normal cells.

Nakamura S, Masegi T, Fukuoka M, Kitai K, Kato A, Ichikawa Y, Watanabe N, Niitsu Y.

Agric Biol Chem. 1991 Jan;55(1):53-7.

14.

Biological activities of human tumor necrosis factor-alpha and its novel mutants.

Xi T, Shi X, Guo D, Dong X, Xu X, Zhu D.

Biochem Mol Biol Int. 1996 Apr;38(4):855-62.

PMID:
8728116
15.

An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration.

Sato T, Yamauchi N, Sasaki H, Takahashi M, Okamoto T, Sakamaki S, Watanabe N, Niitsu Y.

Cancer Res. 1998 Apr 15;58(8):1677-83.

16.

Differential responses of fibroblasts from wild-type and TNF-R55-deficient mice to mouse and human TNF-alpha activation.

Mackay F, Rothe J, Bluethmann H, Loetscher H, Lesslauer W.

J Immunol. 1994 Dec 1;153(11):5274-84.

PMID:
7525730
17.

A trimeric structural fusion of an antagonistic tumor necrosis factor-α mutant enhances molecular stability and enables facile modification.

Inoue M, Ando D, Kamada H, Taki S, Niiyama M, Mukai Y, Tadokoro T, Maenaka K, Nakayama T, Kado Y, Inoue T, Tsutsumi Y, Tsunoda SI.

J Biol Chem. 2017 Apr 21;292(16):6438-6451. doi: 10.1074/jbc.M117.779686. Epub 2017 Feb 24.

18.

Identification of tumor necrosis factor (TNF) amino acids crucial for binding to the murine p75 TNF receptor and construction of receptor-selective mutants.

Ameloot P, Fiers W, De Bleser P, Ware CF, Vandenabeele P, Brouckaert P.

J Biol Chem. 2001 Oct 5;276(40):37426-30. Epub 2001 Jul 11.

19.

Biological activities of human tumor necrosis factor-alpha and its novel mutants.

Xi T, Shi X, Guo D, Dong X, Xu X, Zhu D.

Biochem Mol Biol Int. 1996 May;38(6):1183-9.

PMID:
8739040
20.

Model complexes of tumor necrosis factor-alpha with receptors R1 and R2.

Fu ZQ, Harrison RW, Reed C, Wu J, Xue YN, Chen MJ, Weber IT.

Protein Eng. 1995 Dec;8(12):1233-41.

PMID:
8869635

Supplemental Content

Support Center